These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 24519692)

  • 1. Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial.
    Mas S; Gassó P; Fernández de Bobadilla R; Arnaiz JA; Bernardo M; Lafuente A
    Hum Psychopharmacol; 2013 Nov; 28(6):586-93. PubMed ID: 24519692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
    Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
    Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial.
    Park CH; Park TW; Yang JC; Lee KH; Huang GB; Tong Z; Park MS; Chung YC
    Int Clin Psychopharmacol; 2012 Mar; 27(2):114-20. PubMed ID: 22241281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol.
    Chung YC; Park TW; Yang JC; Huang GB; Zhao T; Oh KY; Kim MG
    J Clin Psychopharmacol; 2012 Dec; 32(6):778-86. PubMed ID: 23131890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Tauscher-Wisniewski S; Kasper S
    Psychopharmacology (Berl); 2002 Jun; 162(1):42-9. PubMed ID: 12107616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
    Yen YC; Lung FW; Chong MY
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].
    López Ibor JJ; Ayuso JL; Gutiérrez M; Guimon J; Herraiz ML; Chinchilla A; Ayuso JL; González Pinto A; Eguiluz I; Fernández A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996; 24(4):165-72. PubMed ID: 8984849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database.
    Fleischhacker WW; Lemmens P; van Baelen B
    Pharmacopsychiatry; 2001 May; 34(3):104-10. PubMed ID: 11434401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central nervous system effects of haloperidol on THC in healthy male volunteers.
    Liem-Moolenaar M; te Beek ET; de Kam ML; Franson KL; Kahn RS; Hijman R; Touw D; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1697-708. PubMed ID: 20142302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
    Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.
    Allain H; Tessier C; Bentué-Ferrer D; Tarral A; Le Breton S; Gandon M; Bouhours P
    Psychopharmacology (Berl); 2003 Feb; 165(4):419-29. PubMed ID: 12459926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study.
    Corripio I; Ferreira A; Portella MJ; Pérez V; Escartí MJ; Del Valle Camacho M; Sauras RB; Alonso A; Grasa EM; Carrió I; Catafau AM; Alvarez E
    Psychiatry Res; 2012 Jan; 201(1):73-7. PubMed ID: 22281201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
    Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
    Timdahl K; Carlsson A; Stening G
    Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrapyramidal side effects and tolerability of risperidone: a review.
    Owens DG
    J Clin Psychiatry; 1994 May; 55 Suppl():29-35. PubMed ID: 7520906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania.
    Ouyang WC; Hsu MC; Yeh IN; Kuo CC
    Int J Psychiatry Clin Pract; 2012 Sep; 16(3):178-88. PubMed ID: 22404731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls.
    Soyka M; Winter C; Kagerer S; Brunnauer M; Laux G; Möller HJ
    J Psychiatr Res; 2005 Jan; 39(1):101-8. PubMed ID: 15504428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of risperidone and haloperidol on tachykinin and opioid precursor peptide mRNA levels in the caudate-putamen and nucleus accumbens of the rat.
    Mijnster MJ; Schotte A; Docter GJ; Voorn P
    Synapse; 1998 Apr; 28(4):302-12. PubMed ID: 9517839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.